| Date | Title | Description | |
|---|---|---|---|
| 26 Jul 2023 | On buy-back programmes | The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program. | Download |
| 10 May 2023 | On P&L | The Company releases the first quarter 2023 financial results presentation | Download |
| 10 May 2023 | On P&L | The Company releases the press release related to the first quarter 2023 financial results | Download |
| 25 Apr 2023 | On business and financial situation | ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) | Download |
| 21 Feb 2023 | On business and financial situation | The Company releases the full year 2022 financial results presentation. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 21 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 07 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 04 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 01 Sep 2021 | On business and financial situation | ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine | Download |
| 28 Jul 2021 | On business and financial situation | The company releases the press release related to first half 2021 financial results | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 21 Feb 2012 | Información sobre resultados (2) | Download | |
| 21 Feb 2012 | Información sobre resultados | Download | |
| 21 Feb 2012 | Informe Anual de Gobierno Corporativo | Download | |
| 15 Feb 2012 | Cambios en política de inversión, áreas de negocio y líneas de productos | Download | |
| 22 Dec 2011 | Composición del Consejo de Administración | Download |